The objective of this study was to measure the efficacy of Mycobacterium smegmatis as a
surrogate in vitro model for the detection of compounds which are inhibitory to the growth of …

Introduction: Tuberculosis is the leading cause of death from infectious disease. Current
drug therapy requires a combination of antibiotics taken over> 6 months. An urgent need for …

In drug development, there are typically a series of preclinical studies that must be
completed with new compounds or regimens before use in humans. A sequence of in vitro …

Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-
growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL …

The assessment of physiochemical and pharmacological properties at early stages of drug
discovery can accelerate the conversion of hits and leads into candidates for further …

Worldwide, tuberculosis (TB) is responsible for nearly 3 million deaths and 8 million new
patients every year (Corbett et al., 2003). The long duration of chemotherapy with multiple …

Tuberculosis is a disease of global importance for which novel drugs are urgently required.
We developed a whole-cell phenotypic screen which can be used to identify inhibitors of …

Here we describe the development and validation of an intracellular high-throughput
screening assay for finding new antituberculosis compounds active in human macrophages …

Murine models of M ycobacterium tuberculosis infection are essential tools in drug
discovery. Here we describe a fast standardized 9-day acute assay intended to measure the …

Increasing multidrug resistance in Mycobacterium tuberculosis continues to diminish the
number of effective drugs available for treatment of active tuberculosis. Although there are …